LQ 043H / Novamab Biopharma - LARVOL DELTA

Preclinical and Phase I Randomized Study of a Potent Inhalable Nanobody Targeting TSLP for the Treatment of Airway Inflammation. (PubMed, J Allergy Clin Immunol) - "These preclinical and clinical studies robustly establish the safety and efficacy of inhaled LQ043, underscoring its potential as a pioneering inhalation therapy for airway inflammation."

Clinical • Journal • P1 data • Preclinical • Inflammation • Respiratory Diseases • CRLF2 • TSLP